Veröffentlichungsdatum: 9 Juni 2008
Projektträger – zwischengeschaltetes Finanzinstitut
A leading pharmaceutical company carrying out internationally reputable research and development activities.Ort
Beschreibung
The project comprises the financing of expenditure under the Research and Development programmes of a major European pharmaceutical company for the development of new medical treatments in the period 2008-2011.
Ziele
The project supports the development of new medical treatments.
Sektor(en)
Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)
EUR 450 million.
Gesamtkosten (voraussichtlicher Betrag)
EUR 1000 million.
Umweltaspekte
R&D activities included in the project will not materially change current R&D practice and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centers, etc. An EIA therefore is not required by EU Directive 97/11. To be further assessed during appraisal. Compliance of R&D activities with relevant EU legislation will also be verified during appraisal.
Auftragsvergabe
The promoter is a private company not operating in the Utilities sector and is thus not covered by EU Directives on procurement. Procedures followed will be verified during appraisal.
Projektstatus
Unterzeichnet - 18/11/2008